Next Generation Sequencers Market - Forecasts from 2023 to 2028

The next-generation sequencers market is expected to grow at a CAGR of 8.48% from US$25.720 billion in 2021 to US$45.460 billion in 2028

Next-generation sequencing, a massively parallel sequencing technology that enables scalability, ultra-high throughput, and quick speed, can be used to establish the order of the nucleotides in the complete genome. One of the most crucial steps in the entire sequencing methodology is DNA pre-sequencing, which involves prepping the material for the following sequencing reaction, Globally, NGS is being gradually included in clinical laboratory analysis, testing, and illness diagnosis. Pharmacogenomics has made extensive efforts to speed up the drug discovery process. Genome mapping programs, next-generation sequencing applications, healthcare spending, and technology improvements are the main factors driving the worldwide next-generation sequencers market size.

Market Drivers:

Increasing use in diagnosis to raise the demand for next-generation sequencers

Next generation sequencers market is increasing as the nucleotides in the entire genome can be determined using next-generation sequencing (NGS), a massively parallel sequencing method that offers scalability, ultra-high productivity, and fast speed. As it includes preparing the material for the following sequencing reaction, DNA pre-sequencing is one of the most important processes in the overall sequencing protocol. Globally, NGS is being gradually included in medical laboratory analysis, evaluation, and illness diagnosis. Pharmacogenomics has made extensive use of NGS to speed up the drug discovery process. For instance, Predicine, Inc. reported in September 2022 that the US FDA had granted breakthrough device designation to the Predicine CARETM the cfDNA Assay, a Next-Generation Sequencing assay for tumor mutation profiling in cfDNA extracted from liquid biopsy samples from cancer patients.

Increased use of sequencing by synthesis

A significant portion of the sequencing by synthesis technology system can be attributed to the growing accessibility of next-generation sequencing (NGS) systems built on this technology.

The ion semiconductor sequencing, on the other hand, is anticipated to expand quickly throughout the course of the projected period. Ion semiconductor sequencing equipment is sophisticated and affordable in comparison to other DNA sequencing techniques, which affects sector growth. Thus, the broad range of applications for the ion semiconductor sequencing technique will fuel the development of the next-generation sequencing industry. For instance, Next-generation sequencing technology developed by Illumina, known as sequencing by synthesis, is widely used throughout the world. Massively parallel sequencing is supported by Illumina sequencing equipment and supplies utilizing a unique technique that recognizes single bases as they are inserted into developing DNA strands.

Increased demand for targeted re-sequencing

One of the main causes influencing segmental increase is the increasing use of targeted re-sequencing in oncology research. As it can aid researchers in efficiently and successfully analyzing the cancer genome, targeted re-sequencing is being utilized more frequently to examine the cancer genome. In the upcoming years, it is anticipated that this trend will persist and foster segmental expansion. The segment's growth rate is also accelerated by the expanding number of targeted re-sequencing technology breakthroughs and the growing use of targeted re-sequencing in clinical applications is also promoting the next-generation sequencers market share.

Market Restraints:

Data storage and management issues

The next-generation sequencers’ market size is hampered due to the vast amount of data created by next-generation sequencing, as well as its administration and interpretation. NGS still presents great obstacles in terms of data storage, processing, quality control management, and interpretation, which slows the transition from the bench to the bedside despite enormous advances to expand NGS applications from research to clinic. The market expansion of next-generation sequencing is also constrained by the absence of built-in infrastructure for next-generation sequencing because it is an advanced technology that requires significant startup expenses and expert labor which makes it expensive to invest which restrains the market growth.

North America is anticipated to be a significant next generation sequencers marketplace globally

The next-generation sequencer market is anticipated to be dominated by North America, and this trend is anticipated to last for several more years. The use of next-generation sequencing (NGS) technology in routine clinical diagnostic tests is growing in popularity. industry growth is anticipated to be boosted by elements including the rising prevalence of infectious and chronic diseases, rising genomics spending, and rising advances by major industry competitors. For instance, the Canada Cancer Society estimates that 6,700 Canadians, 2,700 of whom were women and 4,000 of whom were males, received a leukaemia diagnosis in 2021.

Market Key Developments:

• In January 2023, in order to enhance companion diagnostics for next-generation sequencing in genetic disorders, QIAGEN and population genomics pioneer Helix in California established a collaborative partnership. By collaborating QIAGEN's broad pharmaceutical and biopharma partnerships, NGS capabilities, and international regulatory expertise with Helix's leading technologies, this agreement provides another step toward applying the power of companion testing to genetic disorders.
• In March 2023, SOPHiA GENETICS announced a new collaboration with Qiagen to improve tumor analysis using next-generation sequencing (NGS). The agreement paired QIAseq reagent technology with the DDM platform. Customers will be able to obtain QIAseq panels processed by SOPHiA DDMTM, a cloud-based platform that analyses data from diverse sources to enable completely new research perspectives, thanks to the agreement. The partnership will initially support homologous recombination repair (HRR), a unique type of biomarker test to find tumors that have specific mutations that may make them vulnerable to PARP inhibitors in oncology, using QIAseq Targeted DNA Pro panels for somatic variant detection.
• In September 2022. The NovaSeq X Series, new production-scale next-generation sequencers, was introduced by Illumina Inc. They will make sequencing faster, more potent, and more environmentally friendly.
• In August 2022. HER2 activating changes (SNVs and Exon 20 Insertion) in patients with non-small cell lung cancer (NSCLC) whose tumors may be applicants for ENHERTU (fam-trastuzumab deruxtecan nxki) as a partner diagnostic (CDx) were identified by the Oncomine Dx Target Test, an NGS-based test, according to a report from Thermo Fisher Scientific.
• In March 2022, the CE-IVD labeled Ion Torrent Genexus Dx Integrated Sequencer, a computerized next-generation sequencing device that produces results in as little as one day, was introduced by Thermo Fisher Scientific. The completely validated system, which is intended for use in clinical laboratories, enables users to do both diagnostic testing and clinical studies on a single instrument. The promise of precision healthcare therapies for patients is now made possible by next-generation sequencing, which has become a crucial tool. Any hospital, even community and regional hospitals, can do automated and simple sequencing with the Genexus Dx Integrated Sequencer.

Segmentation:

By Technology

• Sequencing By Synthesis
• Ion Semiconductor Sequencing
• Single-molecule Real-time Sequencing
• Nanopore Sequencing
• Others

By Application

• Diagnostics
• Drug Discovery
• Biomarker Discovery
• Agriculture & Animal Research
• Others

By End-Use

• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Academics & Research Institutes
• Others

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• China
• Japan
• India
• South Korea
• Indonesia
• Thailand
• Others